Revenue Breakdown
Composition ()
No data
Revenue Streams
Lifecore Biomedical Inc (LFCR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Lifecore, accounting for 95.4% of total sales, equivalent to $26.33M. Other significant revenue streams include Contract development and manufacturing organization ("CDMO") and Fermentation. Understanding this composition is critical for investors evaluating how LFCR navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Lifecore Biomedical Inc maintains a gross margin of 25.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4.72%, while the net margin is -32.12%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively LFCR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, LFCR competes directly with industry leaders such as AVIR and TARA. With a market capitalization of $320.34M, it holds a significant position in the sector. When comparing efficiency, LFCR's gross margin of 25.04% stands against AVIR's N/A and TARA's N/A. Such benchmarking helps identify whether Lifecore Biomedical Inc is trading at a premium or discount relative to its financial performance.
